NEW YORK Pfizer is shifting creative duties on smoking-cessation drug Chantix to mcgarrybowen from McCann HumanCare, the client confirmed today.
Major media spending on the drug totaled $55 milllion in 2007 and nearly $60 million in the first 11 months of 2008, according to Nielsen Monitor-Plus.
Interpublic Group’s McCann HumanCare in New York had handled the business since 2007.
Chantix, which was approved by the Federal Drug Administration in 2006, rang up global sales of $883 million in 2007, its first full year on the market, according to a Pfizer annual report.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in